It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The gut microbiome has a fundamental role in human health and disease. However, studying the complex structure and function of the gut microbiome using next generation sequencing is challenging and prone to reproducibility problems. Here, we obtained cross-sectional colon biopsies and faecal samples from nine participants in our COLSCREEN study and sequenced them in high coverage using Illumina pair-end shotgun (for faecal samples) and IonTorrent 16S (for paired feces and colon biopsies) technologies. The metagenomes consisted of between 47 and 92 million reads per sample and the targeted sequencing covered more than 300 k reads per sample across seven hypervariable regions of the 16S gene. Our data is freely available and coupled with code for the presented metagenomic analysis using up-to-date bioinformatics algorithms. These results will add up to the informed insights into designing comprehensive microbiome analysis and also provide data for further testing for unambiguous gut microbiome analysis.
Measurement(s) | genome •rRNA_16S |
Technology Type(s) | DNA sequencing |
Factor Type(s) | sex •age •Smoking •Weight •Height •Diet •Medication |
Sample Characteristic - Organism | Homo sapiens |
Sample Characteristic - Environment | feces •colon |
Machine-accessible metadata file describing the reported data: 10.6084/m9.figshare.11902236
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Catalan Institute of Oncology (ICO), Oncology Data Analytics Program, Barcelona, Spain (GRID:grid.418701.b) (ISNI:0000 0001 2097 8389); Bellvitge Institute of Biomedical Research (IDIBELL), Colorectal Cancer Group, ONCOBELL Program, Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257); Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona, Spain (GRID:grid.466571.7) (ISNI:0000 0004 1756 6246)
2 Catalan Institute of Oncology (ICO), Oncology Data Analytics Program, Barcelona, Spain (GRID:grid.418701.b) (ISNI:0000 0001 2097 8389); Bellvitge Institute of Biomedical Research (IDIBELL), Colorectal Cancer Group, ONCOBELL Program, Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257); Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona, Spain (GRID:grid.466571.7) (ISNI:0000 0004 1756 6246); Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat, Gastroenterology Department, Barcelona, Spain (GRID:grid.417656.7)
3 Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Cancer Epigenetics and Biology Program (PEBC), Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257)
4 Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat, Gastroenterology Department, Barcelona, Spain (GRID:grid.417656.7)
5 Moisés Broggi Hospital, Digestive System Service, Sant Joan Despí, Spain (GRID:grid.417656.7)
6 Viladecans Hospital-IDIBELL, Endoscopy Unit, Digestive System Service, Viladecans, Spain (GRID:grid.417656.7)
7 Catalan Institute of Oncology (ICO), Oncology Data Analytics Program, Barcelona, Spain (GRID:grid.418701.b) (ISNI:0000 0001 2097 8389); Bellvitge Institute of Biomedical Research (IDIBELL), Colorectal Cancer Group, ONCOBELL Program, Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257); Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona, Spain (GRID:grid.466571.7) (ISNI:0000 0004 1756 6246); University of Barcelona, Department of Clinical Sciences, Faculty of Medicine, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)
8 Catalan Institute of Oncology (ICO), Oncology Data Analytics Program, Barcelona, Spain (GRID:grid.418701.b) (ISNI:0000 0001 2097 8389); Bellvitge Institute of Biomedical Research (IDIBELL), Colorectal Cancer Group, ONCOBELL Program, Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257); Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona, Spain (GRID:grid.466571.7) (ISNI:0000 0004 1756 6246); National Cancer Center Finland (FICAN-MID) and Karolinska Institute, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)